Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial
作者: Bettina SchmitzSvetlana DimovaYing ZhangDaya ChellunMarc De BackerTeresa Gasalla
作者单位: 1Vivantes Humboldt-Klinikum, Zentrum für Epilepsie, Am Nordgraben 2, 13509 Berlin, Germany
2UCB Pharma, Allée de la Recherche 60, 1070 Brussels, Belgium
3UCB Pharma, 8010 Arco Corporate Drive, Raleigh, NC 27617, USA
4UCB Pharma, Chemin du Foriest 1, 1420 Braine-l’Alleud, Belgium
刊名: Epilepsy Research, 2020, Vol.159
来源数据库: Elsevier Journal
DOI: 10.1016/j.eplepsyres.2019.106220
关键词: Antiepileptic drugEpilepsyPsychiatric comorbidityLacosamide monotherapyEfficacyTolerability
原始语种摘要: Abstract(#br)Psychiatric comorbidities are common in patients with epilepsy. A double-blind noninferiority monotherapy trial (SP0993; NCT01243177) enrolled newly diagnosed patients (≥16 years) with focal or generalized tonic-clonic seizures. Patients were randomized 1:1 to lacosamide or carbamazepine controlled-release (carbamazepine-CR). Here, we report data from an exploratory post hoc analysis of patients who reported ongoing psychiatric conditions (Medical Dictionary for Regulatory Activities System Organ Class). Of 886 treated patients in the trial, 126 (14.2%; 64 on lacosamide; 62 on carbamazepine-CR) reported at least one ongoing psychiatric condition at screening, most commonly depression (38.1%), insomnia (27.8%), and anxiety (26.2%). In this subgroup, 32/64 (50.0%) patients on...
全文获取路径: Elsevier  (合作)
影响因子:2.241 (2012)

  • carbamazepine 卡马西平
  • epilepsy 癫痫
  • psychiatric 精神病的
  • monotherapy 硫化物
  • seizure 获得
  • trial 试验
  • efficacy 效验
  • psychosis 精神病
  • newly 重新
  • clonic 无性系的